Another network meta-analysis of RCTs, including participants with T2DM, found that GLP-1 RAs decreased the risk of non-fatal MI (Odds Ratio [OR] = 0.92, 95%CI = 0.85–0.99) when compared to placebo or standard care (Palmer et al., 2021). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.